Presentation 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.pdf حسب Yi Li (1144)

"…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…"

Naringenin decreases mitochondrial function. حسب Lauren A. Eanes (20995499)

Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx حسب Yi Li (1144)

"…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…"

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. حسب Sonia T. Gazeau (21512764)

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" حسب Kira Shaw (18796168)

"…The locomotion values (traces and metrics) are in arbitrary units with larger integers representing a greater displacement of the spherical treadmill, the hemodynamic (Hbt) values (traces and metrics) are a percentage change from the normalised baseline (prior to stimulus presentation), and the corresponding time series vector is presented in seconds. …"

Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis حسب Dijkhorst P.J. (20584910)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. حسب Hongliang Chen (538815)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). حسب Philipp Winder (21615570)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. …"

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. …"

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for access question between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c... حسب David Henderson (4612354)

الموضوعات:

Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues... حسب David Henderson (4612354)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: